Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (5849)	10/30/1998 3:42:00 PM
From: scaram(o)uche	Respond to of 9719

>> Even though the Centocor HA-1A trial was halted due to higher recipient death than placebo death, this could still be due to non-randomness of the degree of illness. << If you want to buy the public line, yes. I was Director, MAb R&D at Cutter/Bayer when the molecule first became available for license from Stanford. We paid a fee for evaluation, intending to take a license. We (Michael Collins' labs did all of the micro, my labs did the serology) characterized the molecule and elected to return it. Centocor subsequently licensed it.